About
PROCEPT BioRobotics is a medical robotics company focused on advancing men's urological health through its flagship Aquablation® Therapy platform. Powered by AI-assisted, computer-guided treatment planning, Aquablation Therapy uses a high-velocity waterjet — rather than heat or sharp instruments — to precisely remove excess prostate tissue causing BPH symptoms. The system offers two robotic platforms: the AquaBeam Robotic System (the original platform) and the next-generation HYDROS Robotic System. Both leverage real-time ultrasound imaging integrated with robotic automation to create individualized treatment maps that maximize tissue resection while protecting surrounding anatomy, including the sphincter and neurovascular bundles responsible for sexual function and continence. This approach ensures predictable, reproducible outcomes regardless of prostate size or complexity. Clinical evidence published in the Canadian Journal of Urology (2022) and Journal of Urology (2023) supports the therapy's safety, efficacy, and durability. The platform is designed for use in hospital operating rooms and surgical centers by trained urologists and surgeons. PROCEPT BioRobotics provides comprehensive support including reimbursement resources, clinical data, and training programs for healthcare providers. The technology is particularly well-suited for patients with complex prostate anatomy and for those prioritizing the preservation of sexual function post-procedure.
Key Features
- AI-Assisted Treatment Planning: Computer-guided planning maps personalized tissue resection paths in real time, maximizing therapeutic accuracy while protecting critical anatomy.
- Ultrasound-Guided Waterjet Ablation: A high-velocity waterjet, directed by real-time ultrasound imaging, removes excess prostate tissue without heat or sharp instruments, minimizing collateral damage.
- HYDROS Next-Generation Robotic System: The HYDROS platform represents the latest evolution of Aquablation Therapy, offering enhanced precision, versatility, and a refined surgical experience for clinicians.
- Works Across All Prostate Sizes and Shapes: Clinically validated across a wide range of prostate anatomies, including complex and large-volume glands where other treatments may be less effective.
- Preservation of Sexual Function and Continence: Robotic precision and anatomy-aware planning significantly reduce risks to the sphincter and neurovascular structures, preserving continence and ejaculatory function.
Use Cases
- Treating symptomatic BPH in men with large or complex prostate anatomy where heat-based or mechanical therapies are less effective.
- Providing BPH relief while preserving ejaculatory function for patients concerned about post-surgical sexual health.
- Equipping hospital urology departments with a reproducible, AI-guided robotic platform for standardized BPH surgical outcomes.
- Serving as a first-line surgical intervention for men seeking long-lasting BPH symptom relief with lower risk of incontinence.
- Supporting urologists in government hospitals and large healthcare systems with advanced robotic tools and comprehensive clinical and reimbursement resources.
Pros
- Clinically Proven Outcomes: Multiple peer-reviewed studies (J Urol, Can J Urol) confirm safe, effective, and durable BPH symptom relief across diverse patient populations.
- Anatomy-Preserving Precision: AI-driven planning protects structures responsible for sexual function and urinary continence, differentiating it from many traditional surgical approaches.
- Prostate Size Agnostic: Effective across all prostate sizes and shapes, offering a versatile solution where other therapies may be limited by anatomy.
- Comprehensive Provider Support: PROCEPT offers reimbursement guidance, clinical data resources, and surgeon training programs to support healthcare system adoption.
Cons
- Hospital/OR Setting Required: Aquablation Therapy must be performed in a surgical center or hospital operating room by a trained urologist, limiting accessibility compared to office-based treatments.
- Specialized Training Needed: Surgeons must complete dedicated training to operate the robotic system, representing an adoption barrier for smaller or resource-limited facilities.
- Enterprise Cost: As a capital medical device sold to hospitals and surgical centers, acquisition and operational costs are significant and not transparent to end patients.
Frequently Asked Questions
What is Aquablation Therapy?
Aquablation Therapy is an AI-powered, ultrasound-guided robotic procedure that uses a high-velocity waterjet to remove excess prostate tissue causing BPH (Benign Prostatic Hyperplasia) symptoms, without heat or sharp instruments.
What is the difference between the AquaBeam and HYDROS Robotic Systems?
The AquaBeam Robotic System is the original platform for Aquablation Therapy, while the HYDROS Robotic System is the next-generation platform offering enhanced precision, versatility, and an improved surgical experience.
Is Aquablation Therapy clinically proven?
Yes. Clinical evidence published in the Canadian Journal of Urology (2022) and Journal of Urology (2023) demonstrates that Aquablation Therapy delivers safe, effective, and durable results regardless of prostate size or shape.
Does Aquablation Therapy affect sexual function?
The procedure is specifically designed to preserve sexual function and continence. The AI-assisted treatment planning protects the neurovascular structures and sphincter, resulting in lower rates of ejaculatory dysfunction compared to many traditional surgical approaches.
Who is a candidate for Aquablation Therapy?
Men with symptomatic BPH across a range of prostate sizes and shapes may be candidates. A urologist or surgeon should evaluate individual patient characteristics, disease profile, and medical history to determine suitability.
